CN110538161A - povidone iodine effervescent tablet for animal delivery room and preparation method thereof - Google Patents
povidone iodine effervescent tablet for animal delivery room and preparation method thereof Download PDFInfo
- Publication number
- CN110538161A CN110538161A CN201910930563.3A CN201910930563A CN110538161A CN 110538161 A CN110538161 A CN 110538161A CN 201910930563 A CN201910930563 A CN 201910930563A CN 110538161 A CN110538161 A CN 110538161A
- Authority
- CN
- China
- Prior art keywords
- povidone
- povidone iodine
- drying
- iodine
- effervescent tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Engineering & Computer Science (AREA)
Abstract
The invention discloses a povidone iodine effervescent tablet used in an animal delivery room, which comprises the following components, by weight, 5-50% of povidone iodine, 5-30% of an acid source, 5-20% of an alkali source, 3-8% of a dissolution promoter, 5-20% of a disintegrating agent, 10-15% of a drying agent, 0.3-2.1% of a surfactant, 0.3-0.7% of a film forming agent and 0.3-0.7% of a filling agent, wherein the sum of the weight percentages of the components is 100%. The invention also provides a preparation method of the povidone iodine effervescent tablet. The povidone iodine effervescent tablet disclosed by the invention has the characteristics of high dissolving speed, good drug effect, small irritation, wide bactericidal spectrum, safety in use, convenience in carrying and the like, can treat and prevent the umbilical cord infection of animals, and can create good economic value and social benefit.
Description
Technical Field
The invention relates to the field of animal disinfection medicines, in particular to a povidone iodine effervescent tablet used in an animal delivery room and a preparation method thereof.
Background
Umbilical cord infection, the most common disease in mammals, is inflammation caused by bacterial infection in the process of cutting umbilical cord, and is one of the problems of harming newborn cattle and sheep. The infectious diseases of newborn cattle and sheep infected by umbilical cord generally include 10 kinds of diseases such as omphalitis, umbilical cord gangrene, cystitis, peritonitis, septicemia, pyelonephritis, lung abscess, liver abscess, purulent meningitis, purulent arthritis, tetanus and the like. The pathogenic bacteria of the umbilical cord infection mainly comprise escherichia coli, streptococcus, staphylococcus, pseudomonas aeruginosa, diplococcus pneumoniae, tetanus bacillus and the like. The morbidity of umbilical cord infection diseases in China generally accounts for about 20% of the total morbidity of newborn cattle and sheep, the mortality can reach more than 80%, and the umbilical cord infection can influence the growth and development of animals to lose the feeding value. At present, the number of large and small farms of various scales in China is not small, and the number and the concentration of pathogens in the breeding environment can reach the harmless degree to livestock only through scientific disinfection, so that the disease of the livestock is prevented or the spread of epidemic diseases is inhibited.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide a povidone iodine effervescent tablet used in an animal delivery room and a preparation method thereof, which can treat and prevent the umbilical cord infection of animals, and the effervescent tablet has safe use and good drug effect and can create good economic benefit and social benefit.
In order to achieve the above object, the first aspect of the present invention provides the following technical solutions:
The povidone iodine effervescent tablet used for the animal delivery room comprises, by weight, 5-50% of povidone iodine, 5-30% of an acid source, 5-20% of an alkali source, 3-8% of a dissolution promoter, 5-20% of a disintegrating agent, 10-15% of a drying agent, 0.3-2.1% of a surfactant, 0.3-0.7% of a film forming agent and 0.3-0.7% of a filling agent, wherein the sum of the weight percentages of the components is 100%.
The povidone iodine is an amorphous soluble compound formed by complexing polyvinylpyrrolidone and iodine, has the characteristics of small irritation to skin, low toxicity, lasting effect, safe and simple use and the like, is used as a main drug of the effervescent tablet, has a bactericidal effect by precipitating protein through free iodine, and has a quick killing effect on bacterial propagules, bacterial spores, fungi and viruses.
As a preferred technical solution, the acid source includes any one of malic acid and citric acid or a mixture thereof, and the alkali source includes any one of sodium bicarbonate and sodium carbonate or a mixture thereof. When the effervescent tablet is used, the alkali source is dissolved in water and reacts with the organic acid source to release carbon dioxide gas, so that an effervescent effect is generated. The effervescent tablet prepared from the components has the advantages that: the effervescent tablet can be dissolved in a short time, is convenient to transport and use, has good disinfection and sterilization effects, and greatly solves the problem of long dissolution time of the povidone iodine in water.
As a preferable technical scheme, the dissolution promoter comprises one or more of polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000, polyethylene glycol 20000, mannitol and sorbitol, and the dissolution promoters such as polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000, polyethylene glycol 20000, mannitol, sorbitol and the like have no influence on the clarity of the solution, are nontoxic and nonirritating, have good moisture retention, lubricity and dispersibility, have a certain dissolution promoting effect on the effervescent tablets, and enable the effervescent tablets to achieve ideal disintegration time limit.
The povidone iodine is sticky and has slow dissolution speed in water, and dissolution can be promoted by adding the dissolution promoter, so that the dissolution time of the effervescent tablet meets the requirement. The alcohol cosolvent can greatly improve the solubility of the povidone iodine.
As a preferable technical scheme, the disintegrating agent comprises one or a mixture of low-substituted hydroxypropyl cellulose, croscarmellose sodium, sodium carboxymethyl starch and microcrystalline cellulose. The disintegrating agents such as low-substituted hydroxypropyl cellulose, croscarmellose sodium, sodium carboxymethyl starch, microcrystalline cellulose and the like are used as components for promoting the disintegration in the tablet, so that the medicine can be disintegrated into small granules, and the dissolution of the medicine can be accelerated after the medicine is disintegrated. Povidone iodine is sticky when meeting water, and easily forms a sticky mass after entering water, and the dissolution time is long, so in order to shorten the dissolution time, the disintegrating agent is added to disintegrate the medicine, so that water can easily enter, and the dissolution is accelerated. The low-substituted hydroxypropyl cellulose, the croscarmellose sodium, the sodium carboxymethyl starch, the microcrystalline cellulose and other swelling agents have strong water absorption swelling property, can destroy the cohesive force of the tablet, realize the disintegration of the tablet, and are very favorable for dissolving various components in the tablet, particularly the main drug povidone iodine, so that the components such as the povidone iodine can quickly exert the drug effect.
as a preferable technical scheme, the surfactant comprises one of sodium dodecyl sulfate, light magnesium carbonate loaded with dodecyl dimethyl betaine (BS-12), alpha-sodium alkenyl sulfonate, sodium dodecyl benzene sulfonate and sodium dodecyl sulfonate or a mixture thereof.
The surfactant can reduce the surface tension of the solution, the dispersibility of the solution has a certain relation with the surface tension, the smaller the surface tension is, the better the dispersion of the solution is, and the better the dispersibility of the effervescent tablet in the solution is. The surfactant can enable the drug effect components carried by the solution to contact the infected part for a long time, thereby achieving good healing effect. The surfactant adopted by the invention is characterized in that light magnesium carbonate loaded with dodecyl dimethyl betaine (BS-12) is selected because BS-12 is sticky liquid and can not be directly dried and tabletted, and the light magnesium carbonate is white amorphous powder, has a flaky porous structure, is small in relative density and light in texture, and has the advantage of not generating additives when the BS-12 is loaded.
as a preferable technical scheme, the film forming agent comprises sodium carboxymethyl cellulose, and the sodium carboxymethyl cellulose can be used for skin grinding operation wound surfaces and traumatic wound surfaces, can control the exudation of wound surface tissue liquid after an animal cuts an umbilical cord, and accelerates the healing speed of the wound surfaces.
As a preferable technical scheme, the drying agent adopts anhydrous magnesium sulfate, and the anhydrous magnesium sulfate can avoid the phenomenon of sticking and flushing of materials in the tabletting process due to the fact that the water content of the materials is too large, so that the production benefit of the effervescent tablets is improved. On the other hand, the drying agent dries the material, and the dried material can increase the fluidity of the material and is beneficial to tabletting. Moreover, as the effervescent tablet is a neutral compound, the effervescent tablet plays a role in dehydration and drying and does not react with organic matters in other components, so that the effervescent tablet is prevented from losing the efficacy.
as a preferred technical solution, the filling agent comprises sodium chloride, and the sodium chloride functions as a binder to ensure that the effervescent tablet can be smoothly molded after tabletting.
As a preferable technical scheme, the povidone iodine effervescent tablet comprises the following components in percentage by weight: 10-40% of povidone iodine, 10-28% of an acid source, 10-20% of an alkali source, 3-6% of a dissolution promoter, 10-20% of a disintegrating agent, 11-14% of a drying agent, 1.0-2.0% of a surfactant, 0.4-0.6% of a film forming agent and 0.5-0.7% of a filling agent, wherein the sum of the weight percentages of the components is 100%.
As a more preferable scheme of the above scheme, in order to ensure drug efficacy, disinfection effect, effervescence time and drug stability, the povidone-iodine effervescent tablet preferably includes the following components in percentage by weight: 30% of povidone iodine, 20% of acid source, 15% of alkali source, 5% of dissolution promoter, 15% of disintegrant, 12% of drying agent, 1.8% of surfactant, 0.5% of film-forming agent and 0.7% of filling agent.
A second aspect of the present invention is to provide a method for preparing povidone-iodine effervescent tablet for use in an animal delivery room, the method comprising the steps of:
(1) Grinding povidone iodine into powder and drying to obtain povidone iodine powder dried substance, and immediately storing the povidone iodine powder dried substance in a dark and sealed way after drying;
(2) Weighing other components except the povidone iodine, respectively grinding the components into powder, and drying to obtain a dried substance corresponding to each component;
(3) Adding the povidone iodine powder dried substance, the dissolution accelerator dried substance and the disintegrant dried substance into a mixing barrel respectively or together, and mixing uniformly to obtain a first mixture;
(4) Adding the acid source drying matter, the drying agent drying matter, the surfactant drying matter, the film forming agent drying matter and the filler drying matter into the first mixture respectively or together, and uniformly mixing to obtain a second mixture;
(5) And adding the alkali source dried substance into the second mixture, uniformly mixing to obtain a third mixture, and tabletting the third mixture to obtain the povidone-iodine effervescent tablet.
In the above preparation method, the drying of the components is aimed at: because the acid source and the alkali source are added into the material, if moisture exists, the acid source and the alkali source can be dissolved together in the mixing and tabletting stages to generate acid-base neutralization reaction, so that the finished product loses the effervescent effect. And (4) step (5).
the purpose of separately mixing the step (3) and the step (4) is to fully mix the povidone iodine, the dissolution accelerator and the disintegrant, thereby being beneficial to improving the dissolution time of the effervescent tablet and avoiding the effervescent tablet from being dissolved too fast.
As a preferable technical scheme of the preparation method, in the step (1), povidone iodine powder is put into an oven with the temperature of 25-45 ℃ to be dried for 3-6 hours, and after the drying is finished, the dried povidone iodine powder is immediately filled into an aluminum foil bag, and the aluminum foil bag is sealed to realize sealed storage in a dark place.
Preferably, in the step (1), the povidone iodine powder is placed in an oven at 40 ℃ to be dried for 4 hours, and as the povidone iodine is easily decomposed by light, after the drying is finished, the dried povidone iodine powder is immediately placed in an aluminum foil bag, and the aluminum foil bag is sealed, so that the povidone iodine powder is sealed and stored in a dark place.
The effervescent tablet provided by the invention is prepared by a direct dry powder tabletting method, so that the required material has good fluidity. If the povidone-iodine powder contains more water, the sticking phenomenon is easily caused in the tabletting process. In addition, if the water content is too much, acid-base reaction is easy to occur when the water is mixed with an acid source and an alkali source, so that the quality of the effervescent tablet is reduced, and therefore, the materials need to be dried, and the stability of the effervescent tablet is ensured. When the povidone iodine powder is dried, the temperature is selected to be 40 ℃ so as to remove the water in the povidone iodine under the premise of keeping the effective components of the povidone iodine stable, and if the temperature is too high, the effective iodine in the povidone iodine can be lost. The drying time is set to be 4 hours, the dryness is better, and the process requirements can be met.
As a preferable technical scheme of the preparation method, in the step (2), the drying operation is carried out in an oven at the temperature of 95-115 ℃, the weight is measured once every 1-2 hours in the process of drying each component, and the weight is measured for multiple times until the weight difference between two adjacent times is not more than 5.0 mg.
Further preferably, in the step (2), the drying operation is performed in a 105 ℃ oven, and in the process of drying each component, the weight is measured once every 1 hour, and the weight is measured for multiple times until the weight difference value measured in two adjacent times is not more than 5.0mg, so that the good flowability of the material is ensured, the sticking is prevented, and the tabletting is convenient.
As a preferable technical scheme of the preparation method, when the surfactant is light magnesium carbonate loaded with dodecyl dimethyl betaine (BS-12), the mesh number of the adopted dodecyl dimethyl betaine powder and the light magnesium carbonate powder is 80-120 meshes, and the water content is less than 0.3%.
as a preferable technical scheme of the above preparation method, in the step (5), a tablet press is used for tabletting the third mixture, the pressure and the tablet weight are adjusted, the tablet weight of the povidone-iodine effervescent tablet is controlled to be 0.8-1.2 g, preferably 1g, and the hardness of the tablet is controlled to be 5-7 kg/cm2, so that the tablet has a certain hardness, and the loss caused by fragments in the transportation process is avoided.
As a preferable technical solution of the above preparation method, the preparation method further comprises: and (6) using an aluminum foil bag to carry out light-proof sealed packaging and storage on the povidone iodine effervescent tablets so as to prevent the finished povidone iodine effervescent tablets from weakening the drug effect or directly causing the finished povidone iodine effervescent tablets to lose the drug effect due to illumination and/or moisture absorption.
Compared with the prior art, the invention has the following beneficial effects:
The povidone iodine effervescent tablet used for the animal delivery room has the characteristics of high dissolving speed, good drug effect, small irritation, wide bactericidal spectrum, safe use, convenient carrying and the like, can treat and prevent the umbilical cord infection of animals, and can create good economic value and social benefit.
By adding the film forming agent, the exudation of wound tissue fluid is controlled, the healing of wounds is accelerated, the problems of difficult delivery, abdominal adhesion and the like of livestock can be prevented, and the film forming agent and the povidone iodine have a synergistic effect. The surface active agent is added, so that the surface tension can be reduced, the smaller the surface tension is, the better the solution is dispersed, the better the dispersibility of the effervescent tablet in the solution is, and the active ingredients carried by the solution can better contact with infected parts by the surface active agent, so that a good healing effect is achieved.
The effervescent tablet provided by the invention can be diluted into solutions with different concentrations according to requirements for sterilization and disinfection.
Detailed Description
the present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto. The reagents, equipment and methods adopted by the invention are all reagents, equipment and methods which are conventionally and commercially available in the technical field and are conventionally used in the technical field.
example 1
the embodiment provides a povidone iodine effervescent tablet used in an animal delivery room, which comprises the following components, by weight, 40% of povidone iodine, 17.5% of citric acid, 10% of sodium bicarbonate, 60008% of polyethylene glycol, 10% of microcrystalline cellulose, 12% of anhydrous magnesium sulfate, 1.0% of light magnesium carbonate loaded with BS-12, 0.5% of sodium dodecyl sulfate, 0.5% of sodium carboxymethylcellulose and 0.5% of sodium chloride.
the preparation method of the povidone iodine effervescent tablet comprises the following steps: putting 12g of povidone iodine powder into a drying oven at 40 ℃ for drying for 4 hours, immediately putting the dried povidone iodine powder into an aluminum foil bag after drying, sealing the aluminum foil bag to realize light-proof sealed storage, mixing 12g of the dried povidone iodine powder, 60002.4 g of polyethylene glycol and 3g of microcrystalline cellulose in a mixer for 10 minutes, and uniformly mixing to obtain a first mixture; then, continuously adding 4.5g of dried citric acid, 3.6g of anhydrous magnesium sulfate, 0.3g of light magnesium carbonate loaded with BS-12, 0.15g of sodium dodecyl sulfate, 0.15g of sodium carboxymethylcellulose and 0.9g of sodium chloride into the first mixture, mixing for 10min, and uniformly mixing to obtain a second mixture; and finally, adding 3g of dried sodium bicarbonate into the mixer, mixing for 10min, and uniformly mixing to obtain a third mixture. And tabletting the third mixture on a single-punch tablet machine, controlling the weight of each tablet to be 1g, controlling the hardness of each tablet to be 5-7 kg/cm2, and finally packaging the pressed tablet finished product by using an aluminum foil bag.
Example 2
The embodiment provides a povidone iodine effervescent tablet used in an animal delivery room, which comprises the following components, by weight, 20% of povidone iodine, 25% of citric acid, 15% of sodium bicarbonate, 60004% of polyethylene glycol, 18% of microcrystalline cellulose, 15% of anhydrous magnesium sulfate, 1% of light magnesium carbonate loaded with BS-12, 1% of sodium dodecyl sulfate, 0.3% of sodium carboxymethylcellulose and 0.7% of sodium chloride.
The preparation steps and the condition parameters related to the steps are the same as those in example 1, and are not repeated herein.
example 3
The embodiment provides a povidone iodine effervescent tablet used in an animal delivery room, which comprises the following components, by weight, 50% of povidone iodine, 14% of malic acid, 14.5% of sodium bicarbonate, 100005% of polyethylene glycol, 5% of low-substituted hydroxypropyl cellulose, 10% of anhydrous magnesium sulfate, 0.3% of light magnesium carbonate loaded with BS-12, 0.2% of sodium dodecyl sulfate, 0.7% of sodium carboxymethylcellulose and 0.3% of sodium chloride.
The preparation steps and the condition parameters related to the steps are the same as those in example 1, and are not repeated herein.
Example 4
The embodiment provides a povidone iodine effervescent tablet used in an animal delivery room, which comprises the following components, by weight, 30% of povidone iodine, 20% of malic acid, 15% of sodium bicarbonate, 100005% of polyethylene glycol, 15% of croscarmellose sodium, 12% of anhydrous magnesium sulfate, 1.5% of light magnesium carbonate loaded with BS-12, 0.3% of sodium dodecyl sulfate, 0.5% of carboxymethylcellulose sodium and 0.7% of sodium chloride.
the preparation steps and the condition parameters related to the steps are the same as those in example 1, and are not repeated herein.
Experimental example:
The products obtained in the above examples were subjected to a sterilization test by a quantitative suspension sterilization test according to 2002 edition of disinfectant technical Specification, wherein the strains used in the test were Escherichia coli and Staphylococcus aureus, and the sterilization results are shown in tables 1 and 2:
Experimental strains: escherichia coli and Staphylococcus aureus.
Experimental drugs: 1 piece of disinfectant dissolved in 100mL of distilled water is prepared from the povidone-iodine effervescent tablets of the embodiments 1 to 4, and the concentration of effective iodine in the prepared disinfectant is less than that for disinfecting the umbilical cord.
TABLE 1 results of the Escherichia coli Sterilization test
TABLE 2 Sterilization of Staphylococcus aureus results
In the experiment, the effective iodine concentration of the effervescent tablets for sterilization in the embodiments 1 to 4 is far lower than the umbilical cord disinfection concentration, the sterilization rate of 3min on escherichia coli and 5min on staphylococcus aureus is over 99.9%, and the sterilization rate meets the sterilization requirement and the national sanitary standard.
The use method of the invention comprises the following steps: according to GB26368-2010 iodine-containing disinfectant sanitary standard, the effective iodine concentration for umbilical cord disinfection is 2-10 g/L. Dissolving the prepared effervescent tablet 1 in 10mL of water, slightly shaking up after dissolving, dipping sterile cotton into povidone iodine with the use concentration after delivering and cutting umbilicus, and wiping the infected part for 2-3 times twice a day.
The povidone iodine effervescent tablets and the commercially available povidone iodine effervescent tablets in the embodiments 1 to 4 of the invention are used for respectively observing the curative effect of treating the umbilical cord infection.
Experimental animals: 30 calves diagnosed as cord inflammation.
Diagnostic criteria: the umbilical cord stump is infiltrated and swollen, and cannot dry and fall off for several days. Redness and swelling around the umbilical hole, pain reaction in the inflammation area around the umbilical hole, such as ulceration and necrosis of the umbilical base, and ulcer in the umbilical hole part after the stump falls off, with purulent secretion, and the wound can not be healed for several days.
therapeutic diagnostic criteria: disappearance of purulent secretion, disappearance of inflammation and wound healing.
The curative effect results are as follows:
The curative effect result shows that the povidone iodine effervescent tablet of the present invention has a better curative effect than commercially available iodophors, and the product prepared in example 4 is the optimal product in consideration of the curative effect and other indexes of the present invention.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and their concepts should be considered to be equivalent or modified within the technical scope of the present invention.
Claims (10)
1. The povidone iodine effervescent tablet used for the animal delivery room is characterized by comprising, by weight, 5-50% of povidone iodine, 5-30% of an acid source, 5-20% of an alkali source, 3-8% of a dissolution promoter, 5-20% of a disintegrating agent, 10-15% of a drying agent, 0.3-2.1% of a surfactant, 0.3-0.7% of a film forming agent and 0.3-0.7% of a filling agent, wherein the sum of the weight percentages of the components is 100%.
2. Povidone-iodine effervescent tablet for use in an animal delivery room as defined in claim 1, wherein the acid source comprises any one of malic acid, citric acid or a mixture thereof, and the alkali source comprises any one of sodium bicarbonate, sodium carbonate or a mixture thereof.
3. Povidone-iodine effervescent tablet for use in an animal delivery room as claimed in claim 1, wherein the dissolution accelerator comprises one or more of polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000, polyethylene glycol 20000, mannitol, sorbitol;
the disintegrant comprises one or mixture of low-substituted hydroxypropyl cellulose, croscarmellose sodium, sodium carboxymethyl starch and microcrystalline cellulose.
4. The povidone-iodine effervescent tablet as defined in claim 1, wherein the surfactant comprises one or a mixture of sodium dodecyl sulfate, light magnesium carbonate loaded with dodecyl dimethyl betaine, sodium alpha-alkenyl sulfonate, sodium dodecyl benzene sulfonate, and sodium dodecyl sulfonate;
The film-forming agent comprises sodium carboxymethylcellulose, the desiccant comprises anhydrous magnesium sulfate, and the filler comprises sodium chloride.
5. Povidone-iodine effervescent tablets for use in animal delivery rooms according to claim 1, characterized by comprising, in weight percentage, the following components: 10-40% of povidone iodine, 10-28% of an acid source, 10-20% of an alkali source, 3-6% of a dissolution promoter, 10-20% of a disintegrating agent, 11-14% of a drying agent, 1.0-2.0% of a surfactant, 0.4-0.6% of a film forming agent and 0.5-0.7% of a filling agent, wherein the sum of the weight percentages of the components is 100%.
6. Povidone-iodine effervescent tablets for use in animal delivery rooms according to claim 5, characterized by comprising, in weight percentage, the following components: 30% of povidone iodine, 20% of acid source, 15% of alkali source, 5% of dissolution promoter, 15% of disintegrant, 12% of drying agent, 1.8% of surfactant, 0.5% of film-forming agent and 0.7% of filling agent.
7. A method for preparing povidone-iodine effervescent tablets for use in animal delivery rooms as claimed in any one of claims 1 to 6, comprising the steps of:
(1) grinding povidone iodine into powder and drying to obtain povidone iodine powder dried substance, and immediately storing the povidone iodine powder dried substance in a dark and sealed way after drying;
(2) Weighing other components except the povidone iodine, respectively grinding the components into powder, and drying to obtain a dried substance corresponding to each component;
(3) Adding the povidone iodine powder dried substance, the dissolution accelerator dried substance and the disintegrant dried substance into a mixing barrel respectively or together, and mixing uniformly to obtain a first mixture;
(4) adding the acid source drying matter, the drying agent drying matter, the surfactant drying matter, the film forming agent drying matter and the filler drying matter into the first mixture respectively or together, and uniformly mixing to obtain a second mixture;
(5) And adding the alkali source dried substance into the second mixture, uniformly mixing to obtain a third mixture, and tabletting the third mixture to obtain the povidone-iodine effervescent tablet.
8. The preparation method of povidone iodine effervescent tablet used in animal delivery rooms as claimed in claim 7, wherein in the step (1), povidone iodine powder is put into an oven at 25-45 ℃ to be dried for 3-6 hours, and after the drying is finished, the dried povidone iodine powder is immediately put into an aluminum foil bag, and the aluminum foil bag is sealed to realize sealed storage in dark place;
In the step (2), the drying operation is carried out in an oven at the temperature of 95-115 ℃, and the weight is measured once every 1-2 hours in the process of drying each component, and the weight is measured for multiple times until the weight difference value measured in two adjacent times is not more than 5.0 mg.
9. the method for preparing povidone-iodine effervescent tablet as claimed in claim 7, wherein when the surfactant is light magnesium carbonate loaded with dodecyl dimethyl betaine, the mesh number of the adopted dodecyl dimethyl betaine powder and light magnesium carbonate powder is 80-120 mesh, and the water content is less than 0.3%;
and (5) tabletting the third mixture by using a tabletting machine, adjusting the pressure and the tablet weight, and controlling the tablet weight of the povidone iodine effervescent tablet to be 0.8-1.2 g and the hardness of the tablet to be 5-7 kg/cm 2.
10. The method of claim 7, further comprising: and (6) carrying out light-resistant sealed packaging and storage on the povidone iodine effervescent tablets by using an aluminum foil bag.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910930563.3A CN110538161A (en) | 2019-09-29 | 2019-09-29 | povidone iodine effervescent tablet for animal delivery room and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910930563.3A CN110538161A (en) | 2019-09-29 | 2019-09-29 | povidone iodine effervescent tablet for animal delivery room and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110538161A true CN110538161A (en) | 2019-12-06 |
Family
ID=68714924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910930563.3A Pending CN110538161A (en) | 2019-09-29 | 2019-09-29 | povidone iodine effervescent tablet for animal delivery room and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110538161A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111603425A (en) * | 2020-06-02 | 2020-09-01 | 意润健康产业（广州）有限公司 | Multifunctional effervescent tablet of skin disinfection cleaning solution and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1729994A (en) * | 2005-07-25 | 2006-02-08 | 华中农业大学 | Povidone iodine effervescence tablet for treating milk cow colpitis, its preparation process and application |
| CN102283246A (en) * | 2011-05-30 | 2011-12-21 | 石家庄科大绿源科技发展有限公司 | Solid chlorine dioxide effervescent tablet and preparation method thereof |
| CN102614214A (en) * | 2012-03-12 | 2012-08-01 | 河北科技大学 | Composite povidone iodine tablet and preparation method thereof |
| CN105084475A (en) * | 2015-07-30 | 2015-11-25 | 上海宇昂新材料科技有限公司 | Disinfection effervescent tablet with water quality purification effect and preparation method of disinfection effervescent tablet |
| CN105943704A (en) * | 2016-04-29 | 2016-09-21 | 青岛市中心医院 | Sterilization disinfectant capable of promoting wound healing after abdominal operation |
-
2019
- 2019-09-29 CN CN201910930563.3A patent/CN110538161A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1729994A (en) * | 2005-07-25 | 2006-02-08 | 华中农业大学 | Povidone iodine effervescence tablet for treating milk cow colpitis, its preparation process and application |
| CN102283246A (en) * | 2011-05-30 | 2011-12-21 | 石家庄科大绿源科技发展有限公司 | Solid chlorine dioxide effervescent tablet and preparation method thereof |
| CN102614214A (en) * | 2012-03-12 | 2012-08-01 | 河北科技大学 | Composite povidone iodine tablet and preparation method thereof |
| CN105084475A (en) * | 2015-07-30 | 2015-11-25 | 上海宇昂新材料科技有限公司 | Disinfection effervescent tablet with water quality purification effect and preparation method of disinfection effervescent tablet |
| CN105943704A (en) * | 2016-04-29 | 2016-09-21 | 青岛市中心医院 | Sterilization disinfectant capable of promoting wound healing after abdominal operation |
Non-Patent Citations (4)
| Title |
|---|
| NULL: "《医药工业》", 31 December 1968, 化学工业出版社 * |
| 刘玉明等: "聚维酮碘泡腾片的制备", 《中国新药杂志》 * |
| 岳晓燕等: "低浓度聚维酮碘用于新生儿脐带消毒的效果观察", 《山西医药杂志》 * |
| 李东光编著: "《实用化妆品制造技术》", 30 April 1998 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111603425A (en) * | 2020-06-02 | 2020-09-01 | 意润健康产业（广州）有限公司 | Multifunctional effervescent tablet of skin disinfection cleaning solution and preparation method thereof |
| CN111603425B (en) * | 2020-06-02 | 2023-03-14 | 意润健康产业（广州）有限公司 | Multifunctional effervescent tablet of skin disinfection cleaning solution and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cooper | Iodine revisited | |
| RU2142273C1 (en) | Gel for curing skin diseases and for disinfection of skin | |
| US6582734B1 (en) | Antimicrobial composition useful for the treatment of bovine mastitis | |
| CN101278896A (en) | Chitosan nano silver gel agent and uses thereof | |
| RU2414902C1 (en) | Bactericidal composition for prevention and treatment of infectious diseases of hoofs in animals | |
| AU2001280574A1 (en) | Antimicrobial composition useful for the treatment of bovine mastitis | |
| CN101496821A (en) | Lactobacillus effervescent tablet and preparation method thereof | |
| CN102550601A (en) | Iodine disinfection liquid and preparation method thereof | |
| US20110171284A1 (en) | Povidone-iodine and sucrose wound healing dressing | |
| CN105640916A (en) | Povidone iodine effervescent tablets with anti-microbial, skin-care and anti-inflammation functions and production process of povidone iodine effervescent tablets | |
| AU2020326309A1 (en) | Liquid dressing compositions and their uses | |
| CZ28634U1 (en) | Hyaluronan and octenidine dihydrochloride-based dental composition | |
| CN110538161A (en) | povidone iodine effervescent tablet for animal delivery room and preparation method thereof | |
| CN102697804B (en) | Solid molecular iodine disinfectant and preparation method thereof | |
| CA2531853A1 (en) | Pharmaceutical formulation comprising levothyroxine sodium | |
| US6863898B2 (en) | Method and composition for treating hairy hoof warts | |
| US8445030B2 (en) | Persistent and fast acting antiseptics and disinfectants based on calcium fluoride | |
| CN102872160A (en) | Nano-silver foaming agent used for sterilizing wounds of scalds and burns and ulcer wounds | |
| CN111345326A (en) | Natural plant disinfection effervescent tablet and preparation method thereof | |
| KR20200081160A (en) | Povidone-Iodine Stable Compositions Containing Sodium Chloride | |
| CN111150712B (en) | Povidone effervescent tablet and preparation process thereof | |
| RU2146136C1 (en) | Antiseptic "katapel" | |
| CN109453192A (en) | A kind of compound hydrochloric acid terramycin alumen borneol effervescent tablet and preparation method thereof | |
| CN101755763A (en) | Disinfection composition for preventing and treating livestock and poultry breeding diseases and prepration method and application thereof | |
| CN103784948B (en) | A kind of effervescent suppository for treating manmmal vagina inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191206 |
|
| RJ01 | Rejection of invention patent application after publication |